Deciphering the role of forkhead transcription factors in cancer therapy

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Forkhead O (FOXO) transcription factors are crucial regulators of cellular processes including cell cycle arrest, apoptosis, and DNA repair.
• Dysregulation or inactivation of FOXO proteins is implicated in the development of various cancers, such as breast cancer, prostate cancer, and leukemia.
• Oncogenic signaling pathways (e.g., PI3K/AKT, RAS/MAPK) can suppress FOXO activity via phosphorylation, leading to nuclear exclusion and degradation, promoting tumorigenesis.

Purpose of the Study:

• To review the regulatory mechanisms governing FOXO transcription factors.
• To elucidate how oncogenic pathways impact FOXO function.
• To highlight potential therapeutic strategies targeting FOXOs for cancer treatment.

Main Methods:

• Literature review of studies on FOXO transcription factors in cancer.
• Analysis of molecular mechanisms regulating FOXO activity, including phosphorylation and posttranslational modifications (acetylation, methylation, ubiquitination).
• Examination of the effects of anti-cancer drugs on FOXO activation.

Main Results:

• FOXO activity is suppressed by oncogenic pathways through phosphorylation-induced nuclear exclusion and degradation.
• Posttranslational modifications like acetylation, methylation, and ubiquitination play a role in modulating FOXO3a function.
• Certain anti-cancer drugs (paclitaxel, imatinib, doxorubicin) can activate FOXO3a by inhibiting suppressive oncogenic pathways.

Conclusions:

• FOXO transcription factors are critical tumor suppressors whose activity is tightly regulated.
• Targeting FOXO pathways represents a promising therapeutic strategy for various cancers.
• Understanding FOXO regulation is key to developing novel anti-cancer treatments.